CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -931.38 Thousand USD | 68.47% |
| 2022 | -2.95 Million USD | -13.61% |
| 2021 | -2.6 Million USD | 14.56% |
| 2020 | -3.04 Million USD | 7.87% |
| 2019 | -3.3 Million USD | 13.26% |
| 2018 | -3.8 Million USD | -105.44% |
| 2017 | -1.85 Million USD | -560.51% |
| 2016 | -280.67 Thousand USD | 47.98% |
| 2015 | -539.52 Thousand USD | -149.63% |
| 2014 | -216.13 Thousand USD | -271.93% |
| 2013 | -58.11 Thousand USD | -3417.62% |
| 2012 | -1652.00 USD | -101.14% |
| 2011 | 144.41 Thousand USD | 229.9% |
| 2010 | -111.17 Thousand USD | 3.26% |
| 2009 | -114.92 Thousand USD | -318.53% |
| 2008 | -27.45 Thousand USD | -18.34% |
| 2007 | -23.2 Thousand USD | -215.89% |
| 2006 | 20.02 Thousand USD | 1212.28% |
| 2005 | -1800.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -206.43 Thousand USD | -20.09% |
| 2024 Q1 | -171.9 Thousand USD | -6.44% |
| 2024 Q3 | -152.28 Thousand USD | 26.23% |
| 2023 Q1 | -346.79 Thousand USD | 27.5% |
| 2023 Q4 | -161.49 Thousand USD | 6.69% |
| 2023 FY | -931.38 Thousand USD | 68.47% |
| 2023 Q2 | 2.14 Million USD | 718.61% |
| 2023 Q3 | -173.08 Thousand USD | -108.07% |
| 2022 Q3 | -635 Thousand USD | 13.04% |
| 2022 FY | -2.95 Million USD | -13.61% |
| 2022 Q1 | -1.11 Million USD | -86.2% |
| 2022 Q2 | -730.26 Thousand USD | 34.23% |
| 2022 Q4 | -478.35 Thousand USD | 24.67% |
| 2021 Q4 | -596.32 Thousand USD | 11.82% |
| 2021 FY | -2.6 Million USD | 14.56% |
| 2021 Q1 | -659.73 Thousand USD | 1.64% |
| 2021 Q2 | -667.86 Thousand USD | -1.23% |
| 2021 Q3 | -676.25 Thousand USD | -1.26% |
| 2020 FY | -3.04 Million USD | 7.87% |
| 2020 Q3 | -690.51 Thousand USD | 20.3% |
| 2020 Q2 | -866.36 Thousand USD | -6.19% |
| 2020 Q1 | -815.85 Thousand USD | 16.73% |
| 2020 Q4 | -670.71 Thousand USD | 2.87% |
| 2019 FY | -3.3 Million USD | 13.26% |
| 2019 Q3 | -779.52 Thousand USD | 13.0% |
| 2019 Q1 | -648.29 Thousand USD | 9.78% |
| 2019 Q2 | -896.04 Thousand USD | -38.22% |
| 2019 Q4 | -979.74 Thousand USD | -25.69% |
| 2018 Q1 | -536.95 Thousand USD | 50.54% |
| 2018 Q4 | -718.57 Thousand USD | 15.64% |
| 2018 FY | -3.8 Million USD | -105.44% |
| 2018 Q3 | -851.75 Thousand USD | 49.94% |
| 2018 Q2 | -1.7 Million USD | -216.87% |
| 2017 Q1 | -102.87 Thousand USD | -54.47% |
| 2017 Q4 | -1.08 Million USD | -129.57% |
| 2017 Q3 | -472.87 Thousand USD | -145.59% |
| 2017 FY | -1.85 Million USD | -560.51% |
| 2017 Q2 | -192.54 Thousand USD | -87.16% |
| 2016 FY | -280.67 Thousand USD | 47.98% |
| 2016 Q3 | -13.84 Thousand USD | 89.92% |
| 2016 Q1 | -50.65 Thousand USD | 75.05% |
| 2016 Q2 | -137.29 Thousand USD | -171.02% |
| 2016 Q4 | -66.6 Thousand USD | -381.05% |
| 2015 Q2 | -56.57 Thousand USD | 55.12% |
| 2015 FY | -539.52 Thousand USD | -149.63% |
| 2015 Q4 | -203.05 Thousand USD | -31.99% |
| 2015 Q3 | -153.84 Thousand USD | -171.94% |
| 2015 Q1 | -126.05 Thousand USD | -7.05% |
| 2014 Q4 | -117.75 Thousand USD | -114.83% |
| 2014 Q3 | -54.81 Thousand USD | -86.84% |
| 2014 Q2 | -29.33 Thousand USD | -106.27% |
| 2014 Q1 | -14.22 Thousand USD | 57.7% |
| 2014 FY | -216.13 Thousand USD | -271.93% |
| 2013 Q2 | -4639.00 USD | 69.35% |
| 2013 Q1 | -15.13 Thousand USD | -204.81% |
| 2013 Q3 | -4712.00 USD | -1.57% |
| 2013 FY | -58.11 Thousand USD | -3417.62% |
| 2013 Q4 | -33.62 Thousand USD | -613.58% |
| 2012 Q2 | -1849.00 USD | 81.95% |
| 2012 Q1 | -10.24 Thousand USD | -105.69% |
| 2012 Q3 | -4000.00 USD | -116.33% |
| 2012 Q4 | 14.44 Thousand USD | 461.05% |
| 2012 FY | -1652.00 USD | -101.14% |
| 2011 Q1 | -8808.00 USD | 66.59% |
| 2011 FY | 144.41 Thousand USD | 229.9% |
| 2011 Q4 | 180.17 Thousand USD | 603.83% |
| 2011 Q3 | -35.76 Thousand USD | -734.34% |
| 2011 Q2 | -4286.00 USD | 51.34% |
| 2010 Q4 | -26.36 Thousand USD | 57.59% |
| 2010 Q3 | -62.16 Thousand USD | -3407.96% |
| 2010 Q2 | -1772.00 USD | 91.51% |
| 2010 Q1 | -20.87 Thousand USD | 80.53% |
| 2010 FY | -111.17 Thousand USD | 3.26% |
| 2009 FY | -114.92 Thousand USD | -318.53% |
| 2009 Q4 | -107.21 Thousand USD | -12195.53% |
| 2009 Q3 | -872.00 USD | 33.99% |
| 2009 Q2 | -1321.00 USD | 76.03% |
| 2009 Q1 | -5510.00 USD | 65.89% |
| 2008 FY | -27.45 Thousand USD | -18.34% |
| 2008 Q2 | -1802.00 USD | 75.17% |
| 2008 Q1 | -7257.00 USD | -98.39% |
| 2008 Q3 | -2245.00 USD | -24.58% |
| 2008 Q4 | -16.15 Thousand USD | -619.6% |
| 2007 Q2 | -9963.00 USD | -35.0% |
| 2007 Q3 | -2129.00 USD | 78.63% |
| 2007 Q4 | -3658.00 USD | -71.82% |
| 2007 FY | -23.2 Thousand USD | -215.89% |
| 2007 Q1 | -7380.00 USD | -121.75% |
| 2006 Q2 | -5514.00 USD | 8.36% |
| 2006 FY | 20.02 Thousand USD | 1212.28% |
| 2006 Q1 | -6017.00 USD | 0.0% |
| 2006 Q3 | -2381.00 USD | 56.82% |
| 2006 Q4 | 33.93 Thousand USD | 1525.16% |
| 2005 FY | -1800.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 30.256% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 81.537% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 94.781% |
| Nascent Biotech, Inc. | -2.22 Million USD | 58.232% |
| Rebus Holdings, Inc. | -664 Thousand USD | -40.268% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.138% |
| Qrons Inc. | -643.67 Thousand USD | -44.697% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -139.079% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.322% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -124.17% |
| Skye Bioscience, Inc. | -13.67 Million USD | 93.188% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.703% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 118.95% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -255.861% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.772% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 67.326% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 39.365% |
| Mesoblast Limited | -84.14 Million USD | 98.893% |
| Marizyme, Inc. | -34.08 Million USD | 97.268% |
| Genus plc | 6.4 Million USD | 114.553% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 109.56% |
| Pharming Group N.V. | -4.87 Million USD | 80.913% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 53.114% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 88.846% |
| ContraFect Corporation | -56.88 Million USD | 98.363% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 79.551% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 33.567% |
| IMV Inc. | -38.67 Million USD | 97.592% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 66.142% |
| MultiCell Technologies, Inc. | -722.81 USD | -128755.439% |
| ONE Bio Corp. | 13.68 Million USD | 106.808% |
| Accustem Sciences Inc. | -3.74 Million USD | 75.139% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.421% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -92.808% |
| Q BioMed Inc. | -3.44 Million USD | 72.969% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 126.31% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 64.553% |
| Biomind Labs Inc. | -1 Million USD | 7.748% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.306% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 67.897% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 85.99% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 50.043% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -3009.575% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 94.131% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 51.807% |
| GB Sciences, Inc. | -1.42 Million USD | 34.433% |
| Alpha Cognition Inc. | -9.7 Million USD | 90.404% |
| HST Global, Inc. | -140.9 Thousand USD | -560.989% |
| CSL Limited | 3.7 Billion USD | 100.025% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 17.204% |
| Halberd Corporation | -75.05 Thousand USD | -1141.013% |
| Enzolytics Inc. | -2.14 Million USD | 56.656% |
| Agentix Corp. | -1.37 Million USD | 32.103% |
| Resverlogix Corp. | -12.74 Million USD | 92.694% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 70.603% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.781% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 10.787% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 68.097% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 41.028% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 72.647% |
| AVAX Technologies, Inc. | 6.69 Million USD | 113.916% |
| Zenith Capital Corp. | -8.94 Million USD | 89.585% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.776% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5246.306% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 62.067% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -443.049% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 53.542% |
| Kadimastem Ltd | -3.04 Million USD | 69.365% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 5.353% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 25.846% |
| BioStem Technologies, Inc. | -7.77 Million USD | 88.027% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -413.199% |
| LadRx Corporation | -3.82 Million USD | 75.641% |
| Cell Source, Inc. | -4.32 Million USD | 78.467% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -35.582% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -35.582% |
| NovAccess Global Inc. | -2.46 Million USD | 62.243% |
| Affymax, Inc. | -15.04 Million USD | 93.81% |
| Itoco Inc. | -919.14 Thousand USD | -1.332% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 78.025% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 16.767% |
| Mobile Lads Corp. | -554.55 Thousand USD | -67.952% |
| CytoDyn Inc. | -18.05 Million USD | 94.842% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -3600.358% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -323.205% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -64.927% |
| SYBLEU INC | -149.18 Thousand USD | -524.333% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 48.722% |
| International Stem Cell Corporation | -663 Thousand USD | -40.48% |
| Bioxytran, Inc. | -3.82 Million USD | 75.619% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1669.339% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -4479.056% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 97.432% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 42.436% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -26.575% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 70.062% |
| Neutra Corp. | -229.48 Thousand USD | -305.855% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 94.69% |
| PureTech Health plc | -146.19 Million USD | 99.363% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 95.666% |
| IXICO plc | -1.43 Million USD | 35.186% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 90.187% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.235% |
| CSL Limited | 3.81 Billion USD | 100.024% |
| Cellectis S.A. | -108.85 Million USD | 99.144% |